Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00687934 · ClinicalTrials.gov registry record · Phase 1
Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors
A Phase 1 study, sponsored by Synta Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
NCT00687934: Completed Phase 1 study, sponsored by Synta Pharmaceuticals.
NCT00687934 is a Phase 1 study that has completed, run by Synta Pharmaceuticals. The registered enrollment target is 53 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00687934, a Phase 1 study, has completed, sponsored by Synta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
An open-label dose escalation study of patients with solid tumors treated with STA-9090 (ganetespib)
Interventions
- DRUG STA-9090
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2007-10 |
| Est. Completion | 2011-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00687934
The ClinicalTrials.gov registry entry for NCT00687934 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Synta Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which STA-9090 is the first listed.
NCT00687934 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00687934 about?
NCT00687934 is a clinical study titled "Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors". An open-label dose escalation study of patients with solid tumors treated with STA-9090 (ganetespib)
What is the current status of trial NCT00687934?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2007-10. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00687934?
The interventions under investigation include: STA-9090 (DRUG).
Who is sponsoring clinical trial NCT00687934?
This trial is sponsored by Synta Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.